PROSTATE CANCER AND BENIGN PROSTATE CHANGE – ARE THERE DIFFERENCES IN DEMOGRAPHIC AND BEHAVIOR CHARACTERISTICS?

Authors

  • Aleksandar Trifunovski University Clinic for Urology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of North Macedonia
  • Sasho Dohchev University Clinic for Urology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of North Macedonia
  • Aleksandra Brzanov-Gavrilovska University Clinic for Anesthesia, Reanimation and Intensive Care - CARIL, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of North Macedonia
  • Josif Janculev University Clinic for Urology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of North Macedonia
  • Sotir Stavridis University Clinic for Urology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of North Macedonia
  • Oliver Stankov University Clinic for Urology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of North Macedonia
  • Jusuf Idrizi University Clinic for Urology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of North Macedonia
  • Martina Ambardjieva University Surgery Hospital “St. Naum Ohridski” Skopje, Republic of North Macedonia

Keywords:

prostate cancer, benign prostate change, demographic characteristics, behavior characteristics, family history

Abstract

Prostate cancer (CaP) is one of the major causes of cancer-related mortality worldwide. The incidence rate increases up to 1 in every 52 men aged 50 - 59 years. The variability in distribution is due to the demographic, behavior, and genetic differences, as well as the lifestyle and the health system quality. The aim of this study was to present and compare the demographic and behavior characteristics of patients with malignant and benign prostate change.

This was a prospective clinical study, conducted during 2018-2020, at the University Clinic for Urology, Clinical Centre “Mother Teresa”, Skopje, Republic of North Macedonia. The study analyzed 90 patients with prostate cancer (CaP), and 106 patients with benign prostate change (BeP). The average age of patients from CaP/ BeP group was 69.2 ± 6.9 vs. 68.4 ± 6.3 years (p = 0.3696). No significant difference was found in patients from both groups related to BMI (p=0.3009), nutritional status (p=0.4634), smoking status (p=0.4831), clinical symptoms (p=0.6951). Patients in CaP group had 2.83 times more history of father with prostate cancer, for OR = 2.83 [95% CI (1.03-7.83)], and 12.11 times significantly more close family members with other malignancies than those in the BeP group, for OR=12.11 [95% CI (2.71-54.02)]. We need more extensive research in this field, having in mind the multiethnic aspect which will help us in more effective prevention and early diagnosis of prostate cancer in our country.

References

Romer A, Parsons S. The Vertebrate Body. Philadelphia, PA: Holt-Saunders International 1977; pp. 471–473. ISBN 978-0-03-910284-5..

Mettlin C, Selenskas S, Natarajan N, Huben R. Beta-carotene and animal fats and their relationship to prostate cancer risk. A case-control study. Cancer 1989; 64(3): 605-612. doi: 10.1002/1097-0142(19890801)64:3<605::aid-cncr2820640307>3.0.co;2-i.

Lumey LH, Pittman B, Wynder EL. Alcohol use and prostatae cancer in U.S. whites: no association in a confirmatory study. Prostate 1998; 36(4): 250-255. doi: 10.1002/(sici)1097-0045(19980901)36:4<250::aid-pros6>3.0.co;2-j.

Hellstrom WJG, ed. "Chapter 8: What is the prostate and what is its function?". American Society of Andrology Handbook. San Francisco: American Society of Andrology 1999. ISBN 1-891276-02-6.

Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991; 63(6): 963-966. doi: 10.1038/bjc.1991.210.

Mettlin C. Recent developments in the epidemiology of prostate cancer. Eur JCancer 1997; 33(3): 340-347. doi: 10.1016/s0959-8049(97)89003-x.

Merril RM, Weed DL, Feuer EJ. The lifetime risk of developing prostate cancer in white and black men. Cancer Epidemiol Biomarkers Prev 1997; 6(10): 763-768. PMID: 9332756.

Tsukise A, Yamada K. Complex carbohydrates in the secretory epithelium of the goat prostate. The Histochemical Journal 16 1984; (3): 311–9.

Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006; 11: 1388-1413. doi: 10.2741/1891.

Grover PL, Martin FL. The initiation of breast and prostate cancer. Carcinogenesis 2002; 23(7): 1095-1102. doi: 10.1093/carcin/23.7.1095.

Parsons JK. Modifiable risk factors for benign prostatic hiperplasia and lower urinary tract symptoms : new aproaches to old problems. J Urol 2007; 178(2): 395-401. doi: 10.1016/j.juro.2007.03.103.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71-96. doi: 10.3322/CA.2007.0010.

Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol 1999; 162(2): 293-306. doi: 10.1016/s0022-5347(05)68543-6.

Winterich JA, Grzywacz JG, Quandt SA, Clark PE, Miller DP, Acuña J, et al. Men’s Knowledge and Beliefs about Prostate Cancer: Education, Race, and Screening Status. Ethn Dis 2009; 19(2): 199-203. PMID: 19537233.

MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006; 17(8): 989-1003. doi: 10.1007/s10552-006-0049-z.

Engeland A, Tretli A, Bjørge T. Height, body mass index, and prostate cancer: a follow-up of 950 000 Norwegian men. Br J Cancer 2003; 89(7): 1237-1242. doi: 10.1038/sj.bjc.6601206.

Plaskon LA, Penson DF, Vaughan TL, Stanford JL. Cigarette Smoking and Risk of Prostate Cancer in Middle-Aged Men. Cancer Epidemiol Biomarkers Prev 2013; 12(7): 604-609. PMID: 12869398.

Sesso HD, Paffenbarger RS Jr, Lee IM. Alcohol consumption and risk of prostate cancer: The Harvard Alumni Health Study. Int J Epidemiol. 2001 Aug;30(4):749-55. doi: 10.1093/ije/30.4.749. PMID: 11511598.

Eeles RA, Dearnaley DP, Ardern-Jones A, Shrearer RJ, Easton DF, Ford D, et al. Familial prostate cancer: the evidence and the cancer research Campaign/British prostate group (CRC/BPG) UK familial prostate cancer study. Br J Urol 1997; 79 Suppl 1: 8-14. doi:10.1111/j.1464-410x.1997.tb00795.x.

Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 2003; 97(8): 1894-1903. doi: 10.1002/cncr.11262.

Grönberg H, Wiklund F, Damber J-E. Age specific risks of familial prostate carcinoma. A basis for screening recommendations in high risk populations. Cancer 1999; 86(3): 477-483. PMID: 10430256.

Anderson DE, Badzioch MD. Breast cancer risks in relatives of male breast cancer patients. J Natl Cancer Inst 1992; 84(14): 1114-1117. doi: 10.1093/jnci/84.14.1114.

Sellars TA, Potter JD, Rich SS, Drinkard CR, Bostick RM, Kushi LH, et al. Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. J Natl Cancer Inst 1994; 86(24): 860-865. doi: 10.1093/jnci/86.24.1860.

Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343(8899): 692-695. doi: 10.1016/s0140-6736(94)91578-4.

Carter BS, Bova CS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150(3): 797-802. doi: 10.1016/s0022-5347(17)35617-3.

Isaacs SD, Kiemeney LALM, Baffoe-Bonnle A, Beaty TH, Walsh PC. Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 1995; 87(13): 991-996. doi: 10.1093/jnci/87.13.991.

Downloads

Published

2023-06-16 — Updated on 2023-07-06

Versions

Issue

Vol. 3 No. 2 (2023): Acad Med J

Section

Original Articles